Dr. John Mascarenhas on the COMFORT-I/II Studies for Ruxolitinib in Myelofibrosis
The studies examined ruxolitinib compared to placebo in the United States (COMFORT-I) and best available therapy in Europe (COMFORT-II) for patients with myelofibrosis.
John Mascarenhas, MD, associate professor of medicine, Mount Sinai Hospital, discusses the COMFORT-I and COMFORT-II studies. The studies examined ruxolitinib compared to placebo in the United States (COMFORT-I) and best available therapy in Europe (COMFORT-II) for patients with myelofibrosis. In both studies ruxolitinib reduced splenomegaly and improving symptoms, mostly by down-modulating inflammitory cytokine signaling.
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
